
    
      The objective of this study was to compare the safety and tolerability of one and two doses
      of influenza virus vaccine, trivalent, types A and B, live cold-adapted liquid (CAIV-T) with
      placebo when administered intranasally to healthy infants aged 6 < 24 weeks.
    
  